Bristol-Myers Squibb Co
BMY45.820USD
+0.230+0.50%
交易中 （美東）報價延遲15分鐘
93.29B總市值
15.45本益比TTM
關於 Bristol-Myers Squibb Co 公司
百時美施貴寶公司是一家生物製藥公司，致力於發現、開發和提供先進藥物，幫助患者戰勝嚴重疾病。該公司提供各種治療類別的產品，包括腫瘤學、血液學、免疫學、心血管和神經科學。其醫藥產品包括化學合成或小分子藥物、通過生物過程產生的產品（稱爲生物製劑）和嵌合抗原受體 (CAR-T) 細胞療法。小分子藥物通常以片劑或膠囊的形式口服，但也使用其他藥物輸送機制。生物製劑通過注射或靜脈輸液給患者給藥。其在線產品包括 Eliquis、Opdivo、Orencia、Pomalyst/Imnovid、Yervoy、Sprycel、Reblozyl、Opdualag、Abecma、Zeposia 等。該公司的產品線包括 Krazati、MRTX1719、RYZ101、KarXT、ORM-6151 和 Repotrectinib。
Bristol-Myers Squibb Co簡介
公司代碼BMY
公司名稱Bristol-Myers Squibb Co
上市日期Mar 17, 1980
CEODr. Christopher S. (Chris) Boerner, Ph.D.
員工數量34100
證券類型Ordinary Share
年結日Mar 17
公司地址Route 206 And Province Line Road
城市PRINCETON
上市交易所NYSE Consolidated
國家United States of America
郵編08543
電話16092524621
網址https://www.bms.com
公司代碼BMY
上市日期Mar 17, 1980
CEODr. Christopher S. (Chris) Boerner, Ph.D.
Bristol-Myers Squibb Co公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
62.72K
-50.00%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
16.70K
+10.70%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
11.07K
+25.18%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Derica W. Rice
Mr. Derica W. Rice
Independent Director
Independent Director
--
--
Ms. Lynelle Hoch
Ms. Lynelle Hoch
President, Cell Therapy Organization, Member of the Leadership Team
President, Cell Therapy Organization, Member of the Leadership Team
--
--
Dr. Deepak L. Bhatt, M.D.
Dr. Deepak L. Bhatt, M.D.
Independent Director
Independent Director
--
--
Mr. Phil Holzer
Mr. Phil Holzer
Senior Vice President, Controller
Senior Vice President, Controller
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
62.72K
-50.00%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
16.70K
+10.70%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
11.07K
+25.18%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
業務USD
名稱
營收
佔比
Eliquis
3.68B
30.00%
Opdivo
2.59B
21.09%
Orencia
963.00M
7.85%
Revlimid
838.00M
6.83%
Yervoy
728.00M
5.93%
其他
3.47B
28.29%
地區USD
名稱
營收
佔比
United States
8.52B
69.44%
International
3.48B
28.37%
other
270.00M
2.20%
業務
地區
業務USD
名稱
營收
佔比
Eliquis
3.68B
30.00%
Opdivo
2.59B
21.09%
Orencia
963.00M
7.85%
Revlimid
838.00M
6.83%
Yervoy
728.00M
5.93%
其他
3.47B
28.29%
股東統計
更新時間: 11月4日 週二
更新時間: 11月4日 週二
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
9.53%
BlackRock Institutional Trust Company, N.A.
4.88%
State Street Investment Management (US)
4.65%
Charles Schwab Investment Management, Inc.
3.48%
JP Morgan Asset Management
3.31%
其他
74.15%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
9.53%
BlackRock Institutional Trust Company, N.A.
4.88%
State Street Investment Management (US)
4.65%
Charles Schwab Investment Management, Inc.
3.48%
JP Morgan Asset Management
3.31%
其他
74.15%
股東類型
持股股東
佔比
Investment Advisor
46.45%
Investment Advisor/Hedge Fund
25.61%
Research Firm
2.95%
Pension Fund
2.59%
Bank and Trust
2.29%
Sovereign Wealth Fund
1.75%
Hedge Fund
1.14%
Insurance Company
0.16%
Family Office
0.06%
其他
16.99%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
4101
1.70B
83.42%
+9.48M
2025Q2
4180
1.70B
83.46%
+31.40M
2025Q1
4287
1.68B
82.63%
+10.66M
2024Q4
4261
1.65B
81.14%
+17.04M
2024Q3
4116
1.60B
78.69%
-22.73M
2024Q2
4105
1.59B
78.35%
-83.12M
2024Q1
4118
1.64B
80.97%
+13.32M
2023Q4
4115
1.60B
78.83%
-46.39M
2023Q3
4042
1.63B
77.83%
-55.50M
2023Q2
4082
1.66B
78.77%
-34.93M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
193.94M
9.53%
+3.47M
+1.82%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
99.37M
4.88%
+1.60M
+1.64%
Jun 30, 2025
State Street Investment Management (US)
94.74M
4.65%
-94.48K
-0.10%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
70.80M
3.48%
+10.20M
+16.82%
Jun 30, 2025
JP Morgan Asset Management
67.41M
3.31%
-2.47M
-3.54%
Jun 30, 2025
Capital International Investors
66.16M
3.25%
-303.34K
-0.46%
Jun 30, 2025
Geode Capital Management, L.L.C.
46.18M
2.27%
+723.46K
+1.59%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
33.57M
1.65%
-1.60M
-4.55%
Jun 30, 2025
Columbia Threadneedle Investments (US)
29.38M
1.44%
+350.53K
+1.21%
Jun 30, 2025
Wellington Management Company, LLP
25.82M
1.27%
+2.09M
+8.83%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月1日 週六
更新時間: 11月1日 週六
機構名稱
佔比
LSV Disciplined Value ETF
83.29%
First Trust NASDAQ Pharmaceuticals ETF
7.02%
VanEck Morningstar Wide Moat Value ETF
4.23%
iShares U.S. Pharmaceuticals ETF
4.22%
VanEck Pharmaceutical ETF
3.69%
Schwab U.S. Dividend Equity ETF
3.66%
Franklin US Dividend Booster Index ETF
3.46%
First Trust Morningstar Dividend Leaders Index Fund
3.11%
Brookstone Value Stock ETF
3.1%
Tema Oncology ETF
3.07%
查看更多
LSV Disciplined Value ETF
佔比83.29%
First Trust NASDAQ Pharmaceuticals ETF
佔比7.02%
VanEck Morningstar Wide Moat Value ETF
佔比4.23%
iShares U.S. Pharmaceuticals ETF
佔比4.22%
VanEck Pharmaceutical ETF
佔比3.69%
Schwab U.S. Dividend Equity ETF
佔比3.66%
Franklin US Dividend Booster Index ETF
佔比3.46%
First Trust Morningstar Dividend Leaders Index Fund
佔比3.11%
Brookstone Value Stock ETF
佔比3.1%
Tema Oncology ETF
佔比3.07%
分紅派息
近5年累計派現
22.71B
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Dec 11, 2024
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option
Jan 03, 2025
Feb 03, 2025
Jan 03, 2025
Sep 10, 2024
BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option
Oct 04, 2024
Nov 01, 2024
Oct 04, 2024
Jun 18, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option
Jul 05, 2024
Aug 01, 2024
Jul 05, 2024
Mar 01, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option
Apr 05, 2024
May 01, 2024
Apr 04, 2024
Dec 06, 2023
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option
Jan 05, 2024
Feb 01, 2024
Jan 04, 2024
Sep 20, 2023
BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023
Oct 06, 2023
Nov 01, 2023
Oct 05, 2023
Jun 14, 2023
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Aug 01, 2023 going ex on Jul 06, 2023 with reinvestment option
Jul 07, 2023
Aug 01, 2023
Jul 06, 2023
Mar 03, 2023
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on May 01, 2023 going ex on Apr 06, 2023
Apr 10, 2023
May 01, 2023
Apr 06, 2023
Dec 08, 2022
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Feb 01, 2023 going ex on Jan 05, 2023
Jan 06, 2023
Feb 01, 2023
Jan 05, 2023
Sep 14, 2022
BMY.NB Final Cash Dividend of gross USD 0.54 paid on Nov 01, 2022 going ex on Oct 06, 2022
Oct 07, 2022
Nov 01, 2022
Oct 06, 2022
查看更多
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
